(079) Predictors of Failed Trial of Void After Rezum Water Vapor Therapy for Benign Prostatic Hyperplasia
Abstract
Benign prostatic hyperplasia (BPH) is a common condition that affects a significant portion of men in mid to late adulthood. Rezum water vapor therapy, a minimally invasive intervention that utilizes convective water vapor energy to reduce prostatic tissue volume and alleviate obstruction, has demonstrated favourable safety and efficacy in treating BPH. Post-treatment, patients are discharged with a Foley catheter insertion and undergo a trial of void (TOV) at catheter removal. Failure to void at this time results in re-catheterization, prolonging patient discomfort and increasing the risk of urinary tract infection and other catheter-associated complications. Despite growing data on Rezum water vapor therapy as a treatment for BPH, there is limited data on predictors of post-operative trial of void success.
This study aims to identify clinical and procedural variables associated with failed TOV following Rezum therapy, aiming to contribute to the limited literature on outpatient Rezum outcomes.
We conducted a retrospective study of patients undergoing Rezum water vapor therapy at a Canadian ambulatory surgical centre from April 2022 to November 2024. Data was collected retrospectively from patients who were over the age of 18, receiving Rezum water vapor therapy, and were not using a Foley catheter prior to the procedure. Baseline characteristics, number of injections, and post-operative progress markers were recorded. Univariate logistic regression analysis for each…
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.